Nexelis, a portfolio company of Ampersand Capital Partners, and a leading provider of assay development and advanced laboratory testing is pleased to announce the signing of a definitive agreement, subject to conditions precedent, to acquire ImmunXperts. The closing of the transaction is expected by the end of March. Based in the Brussels South Charleroi Biopark within the town of Gosselies, ImmunXperts has developed and performs a full offering of immunogenicity and immuno-oncology in vitro functional and potency assays. These assays help pharmaceutical and biotech sponsors screen, select and optimize lead compounds before the initiation of in vivo trials.
Read the full article: Nexelis to Acquire Specialty Immunogenicity and Immune-Oncology Testing Laboratory ImmunXperts //
Source: https://www.prnewswire.com/news-releases/nexelis-to-acquire-specialty-immunogenicity-and-immune-oncology-testing-laboratory-immunxperts-301015709.html